This article is more than 5 years old. Information may no longer be current.

Allegro receives $2 million grant to support phase 2 study of Luminate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allegro Ophthalmics has been awarded a $2 million grant from the Type 1 Diabetes Program of the Leona M. and Harry B. Helmsley Charitable Trust, according to a press release.

The grant will support the company’s phase 2 study of Luminate (ALG-1001) for the treatment of diabetic macular edema.

The 6-month randomized, double-masked, multicenter trial, which began in October 2014, is evaluating the safety and efficacy of intravitreal injections of Luminate in comparison to standard care for DME, the release said. One hundred fifty patients are expected to be enrolled in the trial.

The $2 million grant follows a recent $20 million investment and licensing agreement for Luminate in Korea and China from Hanmi Pharmaceutical in exchange for additional economic terms, the release said.